Pulmonary Hypertension (Detail)

USMLE Step 1 trap: Applies Group 1 PAH vasodilator therapy to all WHO groups of pulmonary hypertension. Pulmonary vasodilators are indicated for Group 1 PAH; Groups 2 and 3 are managed by treating the underlying cause (heart failure or lung disease), and vasodilators can be harmful in Group 2.

Pulmonary hypertension (PH) is defined as a mean pulmonary arterial pressure ≥25 mmHg at rest, confirmed by right heart catheterization. The WHO divides it into five groups based on etiology — Group 1 is true pulmonary arterial hypertension (PAH), Group 2 is left heart disease, Group 3 is lung disease/hypoxia, Group 4 is chronic thromboembolic disease (CTEPH), and Group 5 is miscellaneous. USMLE Step 1 tests this heavily because students routinely collapse all five groups into one disease and misapply Group 1 therapy everywhere — a clinically dangerous and exam-punishing mistake.

The exam hits this from multiple angles. You'll see vignettes requiring you to classify PH by etiology, interpret right heart catheterization data (especially PCWP), identify the histopathologic hallmark of severe PAH, and choose group-appropriate therapy. Application and passage interpretation dominate — you won't just be asked to define PH, you'll be handed a cath report and asked what it means or given a patient with COPD and asked what happens if you give sildenafil. The diagnostic distinction between pre-capillary (normal PCWP) and post-capillary (elevated PCWP) PH is the single most tested hemodynamic concept here.

What makes this tricky is the layered logic: the pathophysiology drives the classification, which drives the workup, which drives the treatment. Students who memorize facts in isolation get burned when the stem presents an atypical scenario. Know that cor pulmonale — RV hypertrophy and failure from pulmonary disease — is the cardiac consequence of PH, not LV failure. And know that plexiform lesions are the pathognomonic finding of severe Group 1 PAH on histology. USMLE Step 1 rewards students who can move fluidly across all four of these angles in a single question.

From real student decks

89%have cards covering this topic

84%have mature cards

1median lapses in 14 days

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake

Wrong: All pulmonary hypertension is treated with pulmonary vasodilators such as prostacyclins or PDE-5 inhibitors.

Right: Pulmonary vasodilators are indicated for Group 1 PAH; Groups 2 and 3 are managed by treating the underlying cause (heart failure or lung disease), and vasodilators can be harmful in Group 2.

Pulmonary vasodilators like sildenafil, bosentan, and epoprostenol are specifically indicated for Group 1 PAH, where the primary problem is intrinsic pulmonary vascular disease. In Group 2 (left heart disease), the elevated pulmonary pressure is a downstream consequence of elevated left-sided filling pressures — giving a vasodilator can increase pulmonary blood flow into a congested left heart and worsen pulmonary edema. For Group 3, treating the hypoxia and underlying lung disease is the priority, not vasodilating already-diseased vasculature.

Common mistake

Wrong: Pulmonary capillary wedge pressure (PCWP) is elevated in all forms of pulmonary hypertension.

Right: Elevated PCWP (>15 mmHg) indicates post-capillary (Group 2, left heart disease) pulmonary hypertension; pre-capillary PAH (Group 1) has a normal PCWP.

PCWP reflects left atrial and left ventricular end-diastolic pressure. In Group 2 PH (left heart disease), the high left-sided pressures back up into the pulmonary circulation, causing a high PCWP (>15 mmHg) — the pulmonary vasculature is passively congested. In Group 1 PAH, the problem is intrinsic to the pulmonary arterioles themselves; the left heart is fine, so PCWP is normal (≤15 mmHg). On a Step 1 cath question, elevated PCWP should immediately redirect your thinking to left heart disease as the cause.

Common mistake

Gap: Students miss plexiform lesions as the hallmark histopathologic finding of advanced pulmonary arterial hypertension

Plexiform lesions — disordered proliferation of endothelial cells forming a web-like structure in small pulmonary arteries — are the pathognomonic vascular finding of severe Group 1 PAH.

Plexiform lesions form when disordered endothelial proliferation creates a chaotic web-like channel within small pulmonary arteries — think of it as a failed attempt at recanalization after severe vascular injury. They are specific to advanced Group 1 PAH and are not seen in Groups 2-5. If a histology question shows disorganized glomeruloid tufts within a pulmonary arteriole, the answer is Group 1 PAH, full stop.

Common mistake

Wrong: Pulmonary hypertension causes left ventricular failure as its primary cardiac consequence.

Right: Chronic pulmonary hypertension causes right ventricular hypertrophy and eventually cor pulmonale (RV failure), not primary LV failure.

The pulmonary vasculature sits between the right heart and the lungs, so chronically elevated pulmonary pressures create a pressure overload state for the RV, not the LV. The RV compensates initially with hypertrophy, then decompensates into cor pulmonale — RV dilation, tricuspid regurgitation, and signs of right-sided heart failure (JVD, peripheral edema, hepatomegaly). The LV is typically underloaded in severe PH because less blood gets through the lungs. Don't confuse the cause (elevated pulmonary pressures) with the cardiac victim (the RV).

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Know the WHO five-group classification of pulmonary hypertension and be able to assign a given patient (e.g., someone with mitral stenosis, COPD, or unprovoked DVTs) to the correct group based on the clinical vignette.
Understand the vascular pathology of Group 1 PAH — intimal proliferation, medial hypertrophy, and plexiform lesions — and recognize that progressive RV pressure overload leads to RV hypertrophy and cor pulmonale, not left-sided failure.
Interpret right heart catheterization data to distinguish pre-capillary from post-capillary pulmonary hypertension: a normal PCWP (≤15 mmHg) with elevated mean PAP points to Group 1, while an elevated PCWP (>15 mmHg) points to Group 2 (left heart disease).
Match treatment to the correct WHO group: Group 1 gets targeted vasodilator therapy (prostacyclins, PDE-5 inhibitors, endothelin receptor antagonists); Groups 2 and 3 require treatment of the underlying condition; Group 4 (CTEPH) is treated with anticoagulation and potentially pulmonary thromboendarterectomy.

Can you avoid these mistakes?

A 45-year-old woman with a history of scleroderma presents with exertional dyspnea. Right heart catheterization shows mean PAP of 38 mmHg and PCWP of 10 mmHg. Which WHO group does she belong to, and what is the first-line targeted therapy?

A 68-year-old man with severe mitral stenosis is found to have a mean PAP of 42 mmHg and a PCWP of 22 mmHg on right heart catheterization. Why would starting a PDE-5 inhibitor be inappropriate in this patient?

Pathology from a lung biopsy in a patient with longstanding idiopathic PAH shows disorganized proliferation of endothelial cells forming web-like structures within small pulmonary arterioles. What is this lesion called, and what does its presence signify about disease severity?

A patient with pulmonary hypertension due to COPD develops peripheral edema, elevated JVP, and an enlarged liver on exam. His echocardiogram shows a dilated, hypokinetic right ventricle with preserved left ventricular function. What is the term for this cardiac complication, and which ventricle is primarily affected?

Pulmonary Hypertension (Detail)

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics